AP NEWS

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of WBT, DXC and ALKS

January 9, 2019

NEW YORK, Jan. 09, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Welbilt, Inc. (NYSE: WBT) Class Period: February 24, 2017 to November 2, 2018 Lead Plaintiff Deadline: February 11, 2019

The complaint alleges that throughout the class period Welbilt, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal control over financial reporting; (ii) the Company was incorrectly recording the tax basis of foreign subsidiaries and the amortization of their intangible assets; and (iii) as a result of the foregoing, Defendants’ statements about Welbilt’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On November 5, 2018, Welbilt filed a Form 8-K for its Q3 2018, stating that “During the third quarter of 2018, the Company identified errors in the tax basis of a foreign subsidiary and incorrect amortization of the intangible assets held by the same entity… In addition, the Company discovered certain intercompany transactions were not recorded on a timely basis.” As a result of these errors, Welbilt announced that “the consolidated financial statements of the Company as of and for the year ended December 31, 2016 will be restated, and as of and for the years ended December 31, 2015 and 2017 are expected to be revised.”

Get additional information about the WBT lawsuit: http://www.kleinstocklaw.com/pslra-1/welbilt-inc-loss-submission-form?wire=3

DXC Technology Company (NYSE: DXC) Class Period: February 8, 2018 to November 6, 2018 Lead Plaintiff Deadline: February 25, 2019

The lawsuit alleges that DXC Technology Company made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had changed or planned to change the operations of its sales teams, deploying generalized sales teams as opposed to the specialized teams that were better capable of delivering specialized services to its clients; (b) the Company’s workforce optimization strategy of sharply reducing staff while reducing costs was resulting in a shortage of sales personnel who could execute on demand for services, thereby risking and ultimately losing sales and revenue opportunities; (c) in light of the above, the Company’s revenue and financial performance guidance for the fiscal year 2019 and its reaffirmation of the guidance during the Class Period was without a reasonable basis.

Get additional information about the DXC lawsuit: http://www.kleinstocklaw.com/pslra-1/dxc-technology-company-loss-submission-form?wire=3

Alkermes plc (NASDAQGS: ALKS) Class Period: February 17, 2017 to November 1, 2018 Lead Plaintiff Deadline: February 25, 2019

The lawsuit alleges Alkermes plc made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for its drug ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.

Get additional information about the ALKS lawsuit: http://www.kleinstocklaw.com/pslra-1/alkermes-plc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:J. Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899Fax: (347) 558-9665 www.kleinstocklaw.com

AP RADIO
Update hourly